Skip to main content
HR 4597 116th Congress House Health Health care costs and insurance Medicare Prescription drugs

ACCESS for Biosimilars Act of 2019

Introduced: October 1, 2019 Introduced by: Peters, Scott H. Democratic · California See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 2, 2019
Referred to the Subcommittee on Health.
Oct 1, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 1, 2019
Referred to the Subcommittee on Health.
Oct 1, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 or the ACCESS for Biosimilars Act of 2019

This bill eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

What's happening now October 2, 2019

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 3466 Related bill Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4597: ACCESS for Biosimilars Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-4597/
MLA
"H.R. 4597: ACCESS for Biosimilars Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-4597/.
Bluebook (legal)
H.R. 4597, 116th Cong. (2026), https://openamerica.io/bill/116-HR-4597/.
Markdown link
[H.R. 4597: ACCESS for Biosimilars Act of 2019](https://openamerica.io/bill/116-HR-4597/)
Report a problem